



**NYSE:VNRX**  
**Corporate Deck**

April 2026

# Forward Looking Statements and Disclaimer

Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the size of the market opportunity, the timing of product launches, the timing and success of clinical studies, the timing, completion, success and delivery of data from such studies, the timing of publications, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tool for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Nu.Q® and Capture-PCR™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this document are the property of their respective owners. Additionally, unless otherwise specified, all references to “\$” refer to the legal currency of the United States of America.

# Executive Summary



*Our mission is to save lives and improve outcomes for millions of people and animals worldwide.*

**VolitionRx**

**NYSE: VNRX**

**Medical Devices**

**IP Powerhouse**

**Focus**

**Licensing IP**

**Cancer, Sepsis**

**Low-cost testing**

**Commercial**

**Worldwide Animal**

**\$23M in licensing**

**1st \$1M of Rev**

**Large Unmet Needs**

**Cancer**

**Sepsis**

**Veterinarian**

**Team**

**100s yrs experience**

**56 patent families**

**15 years together**

**Catalysts**


**Cancer Licensing**

**NETs Licensing**


**\$5m Cat Milestone**

**Derisked R&D and Commercial Strategy**

## Measuring chromatin fragments



Cancer



NETs

*Global Experts in Quantifying Nucleosomes*

# Low-cost routine tests

*Platform agnostic; can be adapted to any diagnostic workflow*



**6 hours**

Manual



**45 minutes**

Automated



**<10 minutes**

Point of Care



**<15 minutes**

Lateral Flow

**Asset light - no need for own machines, labs or sales reps**

# Commercialization Strategy

*Underlying principles: low capex, low opex business model focused on commercial partnerships and out-licensing*

## R&D

- ❶ R&D conducted by Volition and its research partners
- ❷ Monetize IP through licensing agreements with:
  - ❶ upfront payments,
  - ❷ milestone payments,
  - ❸ recurring revenue from sales of key components & royalties

## Licensing and partnering criteria:

- ❶ *Broad geographic reach*
- ❷ *Large installed base*
- ❸ *Experience of tech transfer*
- ❹ *Regulatory and clinical affairs*
- ❺ *Large sales and marketing teams*



**2026: Targeting multiple licensing deals in the human space**

# Recent Deals Signed

**werfen**

**HOLOGIC<sup>®</sup>**  
**Diagenode**



- **Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") for Nu.Q<sup>®</sup> NETs**
- **Co-Marketing and Services Agreement for Nu.Q<sup>®</sup> Discover**
- **First Sale of the Nu.Q<sup>®</sup> Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use**

68 patents granted with coverage up to 2044

	<u>TAM</u>	<u>Regulation</u>	<u>Product</u>	<u>Status</u>	<u>Strategy</u>
<b>nu·q cancer</b>	\$4Bn	Lab Developed	Screening/ Management	Clinical Validation	Sales & Licensing
<b>capture seq</b>	\$23Bn	CE Mark/ FDA	Multi-Cancer Early Detection	Proof of Concept	Sales & Licensing
<b>nu·q nets</b>	>\$3Bn ICU/ED	CE Mark/ FDA	NETosis	First sales in EU	Sales & Licensing
<b>nu·q vet</b>	\$170Mn	Non-Regulated	Animal Testing	Launched Worldwide	Licensing
<b>nu·q discover</b>	~\$1Bn	Research Use	Service & Assay Kit	Launched Worldwide	Sales

**capture**  
seq

- World first isolation of transcription factor-DNA from blood
- World first preparation of pure tumor-derived DNA sequence data sets
- A novel class of thousands of new biomarkers
- Compelling proof-of-concept clinical data

**Early detection**

Find cancer early

Improve outcomes

**Finding MRD after treatment**

Adjust treatment

Improve outcomes

**Treatment monitoring**

Assess treatment response









Adjust treatment

Improve outcomes

# Projected Catalysts

Multiple licensing deals in 2025 and 2026

	Catalyst	2025	2026	2027
	Licensing cancer technology			
	Adoption into national screening program(s)			
	Reimbursement / Adoption into routine clinical practice			
	Licensing Multi-Cancer Early Detection			
	Licensing for Human NETosis / Sepsis			
	Sales growth of CE marked product in Europe			
	Automation of Test			
	Wellness plan adoption to drive sales ramp			
	\$5M milestone payment linked to use in felines			
	Co-Marketing agreement			
	Distribution agreement			
	Phase III clinical studies with pharma			

-  Multiple products already launched
-  Proven Licensing model, validated in Vet
-  Strong IP
-  Multiple multi-billion TAM markets
-  Low cost, scalable platform with high margins
-  Asset light - no need for own machines, labs, or sales reps
-  In confidential licensing discussions with around 10 large diagnostic and liquid biopsy companies worldwide, first deals signed in Q3 2025
-  Anticipate use in ***routine*** clinical practice in 2026

# Thank You!